Nuvation Bio Inc. is a clinical-stage company that develops and produces therapeutic products for oncology. The company's lead product candidate is NUV-422, which is a small molecule inhibitor for CDK2, CDK4, and CDK6. In addition to its drug candidates, it has a DDC platform that uses PARP inhibitors to combat ER+ breast and ovarian cancer.